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effectiveness of adding the MAbs cetuximab or bevacizumab to chemotherapy in
the first-line treatment of mCRC patients with KRAS wild-type tumours, from the
UK (UK) NHS perspective. METHODS: A semi-Markov model was developed to
simulate patient outcomes and costs for first and subsequent lines of treatment
including long-term survival after a curative resection of liver metastases. Data for
progression-free survival, resection rates and other model parameters were mainly
derived from the CRYSTAL and NO16966 phase 3 studies. The long-term benefits of
surgery were estimated from a consecutive series of 1439 patients. Resource use
included drugs, physician visits, scans, hospitalizations and treatment of adverse
events. Extensive sensitivity analyses were undertaken to explore the robustness
of the results. RESULTS: In the base case, the estimated mean life expectancy for
cetuximab- and bevacizumab-containing regimens was 3.22 and 2.31 years (all
undiscounted) respectively. The incremental cost-effectiveness ratio (ICER) for
FOLFIRIcetuximab compared with FOLFIRI alone was £30,665 per quality-ad-
justed life year (QALY) and £17,626 per QALY compared with
FOLFOXbevacizumab. The ICER is mainly driven by the number of patients be-
coming resectable and the acquisition cost for each antibody. CONCLUSIONS: This
analysis suggests that cetuximab in combination with FOLFIRI is the most effective
treatment regimen compared with FOLFOXbevacizumab or chemotherapy alone
for patients with KRAS wild-type tumours. The incremental cost-effectiveness ra-
tios of cetuximab in combination with chemotherapy compared with chemother-
apy alone, and bevacizumab-containing regimens are within the commonly ac-
cepted threshold for cost-effectiveness in the UK.
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OBJECTIVES: PFS is an important endpoint in advanced NSCLC as it permits earlier
assessment of treatment benefit compared to overall survival (OS) and is not influ-
enced by subsequent treatment lines. Multiple treatment strategies have demon-
strated PFS benefits in solid tumor oncology, but the economic and humanistic
value of improved PFS remains unclear. METHODS: We developed a literature-
based, 3-state (progression-free, disease-progression, death) Markov model de-
signed to estimate clinical and economic outcomes associated with 2nd-line treat-
ment from a US-payer perspective. Modeled treatments included a commonly used
FDA-approved epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-
TKI) and an equivalent hypothetical intervention with theoretical improvements
applied to quantify value of PFS gains. In base-case, we assumed 20% PFS improve-
ment for intervention and no differences in OS and tolerability profiles or costs
between comparators. Model parameters were pulled from published sources and
included OS, PFS, adverse event rates, health-state utilities, dosing, and costs.
Costs (2010 USD) and effects were discounted 3%. RESULTS: In base-case, projected
total lifetime discounted costs, PFLYs and QALYs were higher for intervention
($30,791; 0.53 PFLY; 0.32 QALY) vs. EGFR-TKI ($26,705; 0.43 PFLY, 0.30 QALY). Sce-
nario analyses identified two major determinants of costs-effectiveness in our
model: PFS improvements accompanied by quality of life (QoL) improvements and
post-progression treatment cost savings. Applying a range of QoL improvements
(10%-30%) resulted in increased lifetime QALYs for intervention (0.35-0.39) such
that ICER was $50,000/QALY with 25% QoL improvements. For QoL improve-
ments 25%, cost-effectiveness can be achieved with post-progression cost
savings. CONCLUSIONS: An intervention conferring PFS improvements may be
cost-effective if modest treatment-related QoL improvements and/or post-pro-
gression cost savings are realized. New and emerging treatments for NSCLC ther-
apies that demonstrate improvement in one or both of these measures and/or OS
and safety benefits will probably be competitive as payers start to weigh cost-
effectiveness measures in coverage decisions.
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OBJECTIVES: Assess clinical and economic outcomes of vaccination (Va) with hu-
man papillomavirus (HPV) 16/18 AS04-adjuvanted vaccine (16/18Vac) added to
screening programmes (Scr) in cervical cancer (CC) prevention, from the National
Healthcare System perspective. METHODS: A lifetime Markov cohort model with
yearly cycles was populated using national epidemiological, cost and treatment
data to simulate the natural history of HPV and assess the effect of VaScr strat-
egies versus Scr alone. Base case considers vaccinating a cohort of 206.788 girls
aged 11, 80% of vaccine coverage and screening each 3 years from age 25 to 65.
Efficacy of 16/18Vac was 95% against HPV-16/18 and cross-protection against 5
oncogenic non-vaccine types of 68%. Outcomes measured were number of CC
cases, CC deaths, quality adjusted life years (QALYs), costs and incremental cost-
effectiveness ratio (ICER) between both strategies. The model also tested a broader
campaign vaccinating both 11 & 18 years old during 7 years (100,000 individuals per
cohort and year) versus vaccination girls aged 11 only. A discount rate of 3% over
costs and outcomes was applied. Sensitivity analyses were performed to assess
influence of different parameters.RESULTS: Base case scenario would avoid 817 CC
cases and 188 deaths (undiscounted) versus Scr alone and generate 1,018 additional
QALYs, resulting in an ICER of € 29.295/QALY (discounted). Vaccination of the co-
horts aged 11 & 18 would avoid 2,448 CC cases and 602 CC deaths (undiscounted)
compared with vaccination only of the 11 years cohort, and represents an ICER of
28,931€/QALY (discounted). Sensitivity analysis shows more favourable cost-effec-
tiveness with higher coverage. CONCLUSIONS: HPV vaccination with 16/18Vac
added to current screening programmes in Spain is a cost-effective strategy. More
favourable cost-effectiveness results may be obtained by expanding vaccination to
18 years old women and increasing vaccination coverage. Results are in accordance
with other studies published at national level.
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OBJECTIVES: Zoledronic acid (ZOL) is the only approved bisphosphonate for SRE
prevention in hormone-refractory prostate cancer (mHRPC). However, in the UK
(UK), 19% and 4% of metastatic, mHRPC patients, do not receive bisphosphonates or
receive non-approved/unproven bisphosphonates (i.e., pamidronate [PAM]), re-
spectively for the prevention of skeletal-related events (SREs). This analysis sought
to estimate, from a UK payer perspective, the cost effectiveness of providing ZOL to
those mHRPC patients not receiving ZOL. METHODS: This analysis was based on
the results of a published randomized phase III clinical trial wherein mHRPC pa-
tients received 15 months of ZOL or placebo (PBO) (Saad et al, 2002). Since PAM
has been shown to be no different than PBO in mHRPC in a pooled analysis of two
trials (Small et al 2003) (i.e., 25% of subjects experienced an SRE at 6 months), the
PBO cohort data from the ZOL trial was as a surrogate for PAM data in the absence
of a direct comparison of ZOL versus PAM (or other bisphosphonates). Costs were
estimated using hospital tariffs and published/internet sources. Quality adjusted
life years (QALYs) gained were based on a previously published analysis of the Saad
et al (2002) data. Survival was assumed to be identical for both groups. RESULTS:
Compared with the use of PAM/PBO, treatment with ZOL (at list price of £174.14/
infusion vs £80/infusion with PAM) resulted in increased QALYs (0.03566/pt),
fewer SREs (-0.8314/pt, i.e., 0.8315 vs 1.6629), and fewer SRE-related costs (-£1,639/
pt, i.e., £2,004 vs. £3,643). Total costs were higher with ZOL (£702/pt). ZOL cost
£19,689/QALY. CONCLUSIONS: The use of ZOL for the prevention of SREs in UK
patients with bone metastases secondary to mHRPC is cost effective relative to
providing no or unapproved bisphosphonates.
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OBJECTIVES: This study aims to identify whether it is desirable to recommend
low-dose aspirin as chemoprevention therapy for colorectal cancer in addition to
routine screening through cost-effectiveness review for general population in
Korea. METHODS: A Markov model was constructed to simulate the disease natu-
ral history of colorectal cancer with routine screening and additional chemopre-
vention by low dose aspirin. The model evaluated hypothetical cohorts of each
100,000 men and women aged from 50 to 70 years old stratified as 5-years interval.
The analysis adopted a social perspective and all costs and outcomes were dis-
counted at 5% for 30 years. The result was presented as the incremental cost per
QALY gained. Uncertainty was explored with deterministic and probabilistic sen-
sitivity analysis. RESULTS: The analysis showed that the use of low dose aspirin in
addition to routine screening comparing to the screening alone is likely to result in
a incremental cost per QALY of around 3,000,000 KRW/QALY to 8,700,000 KRW/
QALY for men over than 50 years old and of around 4,700,000 KRW/QALY to
12,000,000 KRW/QALY for women over than 55 years old. The deterministic sensi-
tivity analysis for uncertain parameters demonstrated that this analysis results
were robust. Assuming a willingness-to-pay threshold of 15,000,000 KRW per QALY
gained, the probabilistic sensitivity analysis suggested that low dose aspirin che-
moprevention is more net benefit than screening alone for both men over than 50
years old and women over than 55 years old. However, there was considerable
uncertainty in the current evidence available. CONCLUSIONS: Low dose aspirin
appears to be cost-effective regardless of the wide distribution of ICER as chemo-
prevention of colorectal cancer coupled with screening comparing to the screening
alone for the men over than 50 years old and women over than 55 years old.
Therefore, low dose aspirin can be recommended as chemoprevention therapy in
Korean population.
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OBJECTIVES: to assess the epidemiological and economic impact of a quadrivalent
human papillomavirus (HPV) types 6/11/16/18 vaccination in Turkey. METHODS: a
published mathematical model of the transmission dynamics of HPV infection and
disease was adapted for Turkey. The model captured direct protective effects of
vaccination and indirect effects (herd immunity). Model inputs were used from
Turkey when available; otherwise, the default values in the original model were
used. The vaccination strategy included HPV vaccination of 12-year-old girls com-
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bined with current cervical cancer screening and HPV disease treatment practices
in Turkey. For the vaccination strategy 85% coverage rate was assumed in the
frame of a mandatory school-based program. Reference strategy was current cer-
vical cancer screening and HPV disease treatment practices in Turkey. Costs were
estimated from the perspective of the Turkish healthcare system, using direct
medical costs associated with the diagnosis and treatment of cervical diseases.
RESULTS: Over 100 years, cumulative % (absolute) reduction in the incidence of
6/11/16/18-related cases of CIN1, CIN2/3, cervical cancer, cervical cancer deaths,
genital warts-female, and genital-warts-male was 78% (4,894), 72% (32,537), 57%
(73,277), 54% (40,513), 86% (404,674), and 86% (409,029), respectively, in the vacci-
nation group compared to the reference group. Number of 6/11/16/18-related CIN1,
CIN2/3, cervical cancer, cervical cancer deaths, and genital warts (both in female
and male population) was halved in the vaccination strategy group compared to
the reference strategy group by year 19, 24, 41, 44, and 14, respectively. The incre-
mental cost-effectiveness ratio for routine vaccination of 12-year-old girls was
18,251 TRY/QALY over 100 years. CONCLUSIONS: A quadrivalent HPV vaccination
program can reduce the incidence of cervical cancer, CINs and genital warts in
Turkey at a cost-per-QALY ratio within the range defined as cost effective.
PCN76
COST-EFFECTIVENESS ANALYSIS OF COMPLIANCE WITH CLINICAL PRACTICE
GUIDELINES IN SARCOMA TREATMENT: AN ECONOMIC EVALUATION IN TWO
EUROPEAN REGIONS
Perrier L1, Buja A2, Mastrangelo G2, Sandona P2, Ducimetière F1, Blay JY1, Gilly FN3,
Siani C4, Biron P1, Ranchère-Vince D1, Decouvelaere AV1, Thiesse P1, Bergeron C5,
Rossi CR2, Ray-coquard I1
1Cancer Centre Léon Bérard, Lyon, France, 2University of Padova, Padova, Veneto, Italy,
3University hospital Lyon Sud, Pierre Bénite, France, 4University Claude Bernard Lyon1, Lyon,
France, 5Institut d’Hémato-Oncologie Pédiatrique, Lyon, France
OBJECTIVES: Sarcomas are rare tumours (1-2% of all cancers) with high discor-
dance in diagnosis and low compliance with clinical practice guidelines (CPG). The
objective was then to perform a cost-effectiveness analysis (CEA) of compliance
with CPG compared to non compliance in the treatment of sarcoma. METHODS:
The study included patients aged15 years with histological diagnosis of sarcoma
treated at the University hospital of Lyon and/or Léon Bérard Cancer centre (Rhône-
Alpes region, France) in 2005/2006 or in public hospitals of Veneto (Italy) in 2007.
The time horizon was three years post diagnosis. The hospital’s perspective was
adopted, based on a microcosting approach. All costs were expressed in euros 2009.
A 4% annual discount rate was applied to both costs and effects. Incremental Cost
Effectiveness Ratios (ICER) were expressed as costs per life year gained, per disease-
free year gained, and per relapse-free year gained when treatments were compli-
ant with CPG compared to not compliant. Probabilistic sensitivity analyses were
performed based on 10000 bootstrap replications both with and without adjusting
data to grade. RESULTS: A total of 219 patients were included in the study. Com-
pliance with CPG was observed for 118 patients (54%). Average total costs reached
€23,571 when treatment was in accordance with CPG and €27,313 otherwise. Com-
pliance with CPG strictly dominates for disease-free and relapse-free survivals.
When handling uncertainty, probabilities that compliance with CPG still strictly
dominates were 33%, 63% and 88% for overall, disease-free, and relapse-free sur-
vivals, respectively. When costs and effects were adjusted to grade, probabilities
reached 17%, 48% and 75%, respectively. CONCLUSIONS: Given that few cost-ef-
fectiveness analyses have examined compliance with CPG in rare tumours, these
results are promising and should encourage physicians’ efforts to increase their
compliance to CPG.
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OBJECTIVES: To estimate the cost-effectiveness of G-CSF PP strategies versus peg-
filgrastim SP and G-CSF SP strategies versus no prophylaxis for decreasing FN
incidence in patients treated with cytotoxic chemotherapy for stages 2 and 3 breast
cancer. METHODS: A Markov model was designed to track health outcomes (FN
events) and medical direct costs (G-CSF, administration and FN episode costs, cal-
culated with French Sickness Fund perspective). The model compared 9 prophy-
laxis strategies for three frequent BC chemotherapies (TAC [docetaxel, doxorubi-
cin, cyclophosphamide], TC [docetaxel, cyclophosphamide] and AC-T
[doxorubicin, cyclophosphamide—docetaxel]): pegfilgrastim (Neulasta®), 6-day
filgrastim (Neupogen®), 11-day filgrastim, 6-day lenograstim, as either PP (initiated
from first cycle) or SP (initiated after FN event), or no prophylaxis. Inputs included
transition probabilities (relative FN risks depending on the chemotherapy, deter-
mined from expert opinion and published studies: TAC, 25%; TC, 10% and AC-T 7%
for AC and 21% for T), FN history and chemotherapy cycle), as well as unit costs for
prophylaxis resources and overall cost associated with FN. Incremental cost-effec-
tiveness ratios (ICERs) were expressed per FN event avoided. PP strategies were
compared to SP with pegfilgrastim and SP strategies were compared to no
prophylaxis. RESULTS: In the high risk population (chemotherapy FN risk 20%),
PP-pegfilgrastim was the most cost-effective PP-G-CSF versus SP-pegfilgrastim.
With TAC, ICER was €8,383 per FN avoided. In less cytotoxic regimens without
considering patient risk factors, after an FN event, SP-pegfilgrastim was the most
cost-effective SP-G-CSF compared to no prophylaxis, with ICERS ranging from
€4614 with TC to €4795 with AC-T.CONCLUSIONS:According to our model based on
French cost data, pegfilgrastim in PP and SP is more cost-effective than PP and SP
with filgrastim and lenograstim in BC. PP-pegfilgrastim is the most cost-effective PP
strategy in case of high risk of FN.
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OBJECTIVES: Colorectal cancer (CRC) is one of the most prevalent forms of cancer
worldwide. This review aims to report on the most recent clinical and cost-effec-
tiveness data available for five of the most often used drugs in the treatment of
advanced (ACRC) and non-advanced CRC; oxaliplatin, irinotecan, bevacizumab,
panitumumab and cetuximab. METHODS: A systematic review of the literature
was performed for the clinical effectiveness. Articles were divided on type of CRC,
ACRC or non-advanced CRC , and for ACRC on time point of treatment (1st, 2nd or
3rd line). If possible, data on overall survival (OS) and progression free survival (PFS)
were extracted. An additional systematic review was performed to identify cost-
effectiveness analyses performed for non-advanced CRC and ACRC, from which
total costs, total gains (LYG or QALYs) and ICERs were extracted. RESULTS: Regard-
ing clinical effectiveness, our search identified seven articles for oxaliplatin, six for
irinotecan, four for bevacizumab five for cetuximab and four for panitumumab.
The cost-effectiveness search yielded 6 articles for non-advanced CRC and 17 arti-
cles for ACRC. Clinical effectiveness has been demonstrated in the literature for
oxaliplatin, irinotecan and bevacizumab, with on average approximately two to
three months additional survival. Effectivness of panitumumab and cetuximab has
mainly been demonstrated on PFS, where on average 2 months is gained. The ICERs
of oxaliplatin for non-advanced CRC were between £2,970 and $24,104/QALY. ICERs
reported oxaliplatin and irinotecan combination therapy vs monotherapy with
5-FUin ACRC are between $10,137/LYG and £58.400/progression free LYG. ICERs for
bevacizumab, cetuximab and panitumub in addition to combination chemother-
apy in advanced CRC, when reported, are between €17.000/LYG and $299,613/QALY
CONCLUSIONS: Clinical effectiveness of oxaliplatin, irinotecan, bevacizumab, ce-
tuximab and panitumab has been established. However, it is not clear whether the
use of these drugs is also cost-effective, especially not for bevacizumab, cetuximab
and panitumumab.
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OBJECTIVES: Weekly gemcitabin and erlotinib are both active in elderly patients
treated for NSCLC. The aim of the GFPC0505 randomized phase II trial was to
compare the efficacy and the cost of weekly gemcitabin (G) followed by erlotinib
after progression (arm A) versus erlotinib followed by G after progression (arm B) in
frail elderly patients with advanced non small-cell lung cancer (NSCLC), selected
on the basis of a comprehensive geriatric assessment (CGA). METHODS: Frail el-
derly chemotherapy-naive patients with stage IIIB/IV NSCLC were selected after a
CGA. Main clinical outcome was time to second progression (TTP2). Costs were
limited to direct medical costs and were prospectively collected until progression,
from the third party payer perspective. Health utilities (based on disease states and
grade 3-4 toxicities) and costs after progression were derived from the literature.
Sensitivity analyses were performed. RESULTS: Median age of the 94 enrolled pa-
tients was 78.2 years, and 76 (80%) were male. There is no significantly difference
between the 44 and 50 patients respectively randomized in arm A and B, in terms of
efficacy (TTP2: 4.3 and 3.5 months: overall survival: 4.4 and 3.9 months, mean
QALY:0.347 and 0.325) and in terms of mean direct costs (15,363 and 15,233€).
CONCLUSIONS: In this population, the 2 strategies appeared equivalent in terms of
efficacy and costs. Supported by an unrestricted educational grant from Roche
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OBJECTIVES: To evaluate whether the use of bevacizumab  paclitaxel offers best
cost-effective results regarding the use of paclitaxel for patients with metastatic
breast cancer mBC METHODS: The treatment was evaluated up to the progression
of the disease, rescue management and palliative up to to death in a Markov model,
operating 65 cycles of 28 days. An incremental cost effectiveness analysis and
sensitivity analysis was performed considering as an outcome measure progres-
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